Does Insurance Cover Psychedelic-Assisted Psychotherapy

Reimbursify: Simplify Out-of-Network Health Insurance Claims

Effortlessly file out-of-network health insurance claims with Reimbursify. Save time, reduce stress, and maximize your reimbursements with our easy-to-use app

Reimbursify

Verify your insurance benefits through Reimbursify

For Clients

ClientNew York

Focus on you. Not the cost of therapy. Thrizer helps you successfully navigate your out-of-network benefits, saving you thousands on therapy and all the insurance headache

Psychedelic-Assisted Psychotherapy — Rates, Referrals & Registration

Psychotherapy therapy, support, and case management via telehealth from the Psychedelic Institute of Mental Health & Family Therapy

Psychedelic Institute of Mental Health & Family TherapyMichael DeMarco, PhD

Michael DeMarco, LMFT, PhD, Founding Fellow

Board Certified Clinical Sexologist & Certified Sex Therapist, Licensed Marriage & Family Therapist, Licensed Mental Health Counselor, Ketamine Psychedelic Preparation & Integration, Cognitive Behavioral Therapy, Existential Therapy | Telehealth CA, NY, UT, VT

Psychedelic Institute of Mental Health & Family TherapyMichael DeMarco, PhD

Headway Telehealth Therapist Aetna, Anthem Blue Cross, Blue Cross Blue Shield of Massachusetts, Blue Shield of California, Cigna, Horizon Blue Cross and Blue Shield of New Jersey, Point32 Healthcare, Quest Behavioral Health, and Regence BlueCross BlueShield of Utah

Preservative-free formulation of ketamine, NRX-100, Granted FDA Fast-Track Designation for Suicidal Ideation in Patients with Depression, including Bipolar Depression

“Approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – designed to help address national crisis.”

Psychedelic Institute of Mental Health & Family TherapyMichael DeMarco, PhD

IV Ketamine by NRX has received FDA fast-track designation. If approved, iv ketamine for depression and other mental health indications will be accepted by insurance. "NRx will be submitting patient-level data from controlled clinical trials that demonstrate ketamine to be superior to both a placebo and an active comparator, as well as either non-inferior or superior to electroshock therapy in treating various forms of depression, including patients with active suicidal ideation. Although ketamine in various forms is increasingly used to treat depression and related disorders, it is currently only approved by FDA only for use as an anesthetic and, therefore, not reimbursed by most insurance carriers for treatment of suicidality or depression. Intravenous ketamine is reimbursed by the Department of Veterans Affairs and the Department of Defense for its beneficiaries. By applying for FDA labeling for NRX-100 to treat suicidal depression, the Company hopes to make this potentially life-saving therapy available to all Americans, not just those who are able to pay out of pocket."